Effective tissue procurement and utilization is vital for meaningful translational research activities. The Tissue Procurement and Hematopathology Core will work with each SPORE project and the Biostatistics and Data Management Core to ensure efficient and highly-coordinated procurement, use and storage of blood and bone marrow samples. The Core will obtain and maintain a repository of blood samples (including peripheral blood, bone marrow biopsies, and bone marrow aspirates) for laboratory use, with an effective coding system for all laboratory specimens to ensure patient confidentiality and prevent experimental bias. Continuous communication between the investigators, research nurses, biostatisticians and hematopathologists, as well as standardized operating procedures for activities will provide for optimal tissue collection and accurate processing, analysis and storage of each sample. Thus, the functions of the Pathology and Tissue Core are to facilitate acquisition, preservation, analysis and dispersal of clinical samples and to provide hematopathologic characterization and specimens for all project investigators. The Tissue Procurement and Hematopathology Core has the following objectives: ? Develop and maintain a repository of blood and bone marrow specimens, including intact cells, serum, cellular DNA, RNA and protein, from patients with leukemia and MDS (including patients who are newly diagnosed, in remission and/or in relapse) receiving care or evaluation at M.D. Anderson Cancer Center. Distribute tissue specimens to SPORE investigators for analysis and provide expertise in the interpretation of studies performed on tissue sections within SPORE projects Provide comprehensive histologic characterization of blood and marrow samples used in SPORE projects, including specimens from patients entered onto clinical protocols. ? Provide stock and customized Reverse Phase Protein Arrays to Spore researchers. ? Maintain a comprehensive, prospective interactive database with detailed clinical and pathologic data for patients with leukemia and MDS receiving care or evaluation at M.D. Anderson Cancer Center ? Facilitate inter-SPORE collaborations through sharing of blood and marrow resources. Lay Abstract: Effective tissue procurement and utilization is vital for meaningful translational research activities. The Tissue Procurement and Hematopathology Core will work with each SPORE project and the Biostatistics and Data Management Core to ensure efficient and highly-coordinated procurement, use and storage of blood and bone marrow samples

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA100632-08
Application #
8141967
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2010-05-01
Budget End
2011-04-30
Support Year
8
Fiscal Year
2010
Total Cost
$232,782
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Fiorini, Elena; Santoni, Andrea; Colla, Simona (2018) Dysfunctional telomeres and hematological disorders. Differentiation 100:1-11
Cortes, Jorge; Perl, Alexander E; Döhner, Hartmut et al. (2018) Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol 19:889-903
Zhang, Weiguo; Ly, Charlie; Ishizawa, Jo et al. (2018) Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial. Haematologica 103:1642-1653
Takahashi, Koichi; Wang, Feng; Morita, Kiyomi et al. (2018) Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nat Commun 9:2670
Ishizawa, Jo; Nakamaru, Kenji; Seki, Takahiko et al. (2018) Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. Cancer Res 78:2721-2731
Kayser, Sabine; Levis, Mark J (2018) Advances in targeted therapy for acute myeloid leukaemia. Br J Haematol 180:484-500
Xia, Fang; Ning, Jing; Huang, Xuelin (2018) Empirical Comparison of the Breslow Estimator and the Kalbfleisch Prentice Estimator for Survival Functions. J Biom Biostat 9:
Trujillo-Ocampo, Abel; Cho, Hyun-Woo; Herrmann, Amanda C et al. (2018) Rapid ex vivo expansion of highly enriched human invariant natural killer T cells via single antigenic stimulation for cell therapy to prevent graft-versus-host disease. Cytotherapy 20:1089-1101
Cortes, Jorge E; Tallman, Martin S; Schiller, Gary J et al. (2018) Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML. Blood 132:598-607
Ohanian, Maro; Rozovski, Uri; Kanagal-Shamanna, Rashmi et al. (2018) MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma :1-12

Showing the most recent 10 out of 487 publications